Your Eye Exam May Soon Predict Heart Disease: Topcon Spins Out AI Platform to Mine Ocular Data for Systemic Health Clues
Oku Digital Health launches with access to 10,000+ care locations, aiming to transform routine eye screenings into early warning systems for cardiovascular, kidney, and other systemic diseases through oculomics.
Topcon Healthcare has unveiled Oku Digital Health, an AI-powered subsidiary designed to bridge the gap between eye care and systemic disease detection. The platform aims to leverage ocular data—images, biomarkers, and diagnostic information captured during routine eye exams—to identify early signs of conditions like cardiovascular and kidney disease, potentially transforming how millions of patients are screened for life-threatening illnesses.
Operating across more than 10,000 connected care locations through Topcon Healthcare's existing infrastructure, Oku represents a strategic pivot for the medical device manufacturer into the emerging field of oculomics: the science of using eye-derived biomarkers to detect systemic health conditions. The platform integrates AI-supported diagnostics, electronic health record (EHR) systems, and clinical referral workflows to connect optometry and ophthalmology practices with primary care physicians and medical specialists.
Dual Market Strategy: Clinical Care Meets Pharmaceutical Research
Oku's business model targets two distinct markets simultaneously. For healthcare providers, the platform creates new pathways for systemic disease screening and referral coordination between eye care professionals and other medical specialties. By analyzing ocular imaging and data captured during routine exams, Oku's AI algorithms aim to flag potential systemic health issues that might otherwise go undetected until symptoms emerge.
For pharmaceutical companies, Oku positions itself as a real-world evidence aggregator, offering access to longitudinal ocular data that could inform drug development and precision medicine initiatives. This dual approach creates multiple revenue streams while establishing Oku as a potential data hub in both clinical diagnostics and pharmaceutical research.
According to the announcement, Topcon Healthcare has invested strategically in software, clinical decision support, and AI technologies over the past five years to realize its "Healthcare from the Eye" vision, setting the stage for Oku's launch.
Leadership Team With Tech and Pharma Pedigree
Oku has assembled a leadership team with experience across technology giants and pharmaceutical companies. Ali Tafreshi serves as CEO of both Oku Digital Health and Topcon Healthcare, having previously held leadership positions at Heidelberg Engineering. Trent Norris joins as COO after serving as global head of business development for digital health at Nvidia, with prior roles at Flywheel.io and Microsoft.
The medical and scientific leadership includes Matthew Lungren, MD, MPH, as Chief Data AI Officer—an adjunct professor of biomedical data science at Stanford University School of Medicine who previously served as chief scientific officer at Microsoft Health and Life Sciences. Daniela Ferrara, MD, PhD, FASRS, FARVO, takes the role of Chief Medical Officer, bringing nearly 11 years of experience as principal medical director of ophthalmology at Genentech, along with her current position as assistant professor of ophthalmology at Tufts University School of Medicine.
Jacques Gilbert rounds out the executive team as Chief Strategy and Business Development Officer, having previously led healthcare strategy, partnerships, and M&A at Microsoft, with earlier positions at Nuance Communications and GE Healthcare.
Industry Debut and Market Positioning
Oku Digital Health will make its public debut at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans, scheduled for October 9-12, 2026. The company will showcase its platform at booth 1737 within the Topcon Healthcare exhibit.
The launch signals Topcon Healthcare's evolution from diagnostic equipment manufacturer to integrated digital health platform provider, positioning the company to compete in the growing oculomics market. If successfully implemented, Oku's approach could enable earlier detection of systemic diseases through routine eye exams, potentially identifying cardiovascular or kidney conditions before clinical symptoms manifest and streamlining care coordination through integrated referral workflows.
Sources
Reporting & accountability
How we maintain accuracy
Health AI Central separates reported facts, analysis, and public-source data. Readers can review our standards, request a correction, or consult the relevant research methodology before relying on a claim.